Brilinta 60 mg (Ticagrelor)

Adult dose

Do not use this medicine in combination with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment is recommended for 12 months unless discontinuation is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who are at increased risk of bleeding and have undergone percutaneous coronary intervention (PCI), monotherapy with this medicine (discontinuation of aspirin) may be considered after 3 months of treatment with this medicine and aspirin. Patients with a history of myocardial infarction (at least 1 year earlier) and at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who received this medicine 90mg or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with this medicine 60mg. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuation of a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the corresponding dosage and administration. Data on the safety and efficacy of this medicine for use beyond 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink immediately. Rinse the glass with another half glass of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is required in patients with renal impairment. No dose adjustment is required in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and there is limited experience with its use in patients with moderate hepatic impairment.

Child dose

The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established.

This medication inhibits the aggregation of platelets in the blood, preventing the formation of blood clots. The risk of bleeding may increase while taking this medication, so patients with bleeding or a history of bleeding should not take it. If surgery is planned, this medication should be discontinued at least 5 days prior to the surgery, and any symptoms of bleeding should be reported to a doctor immediately. This medication should not be taken with strong drugs such as certain antibiotics for patients with severely impaired liver function. Patients at high risk of bleeding or those taking other drugs affecting blood coagulation should use this medication cautiously. Side effects such as dyspnea or bradycardia may occur, so patients with respiratory or heart diseases need to exercise caution. Women who are pregnant or breastfeeding should consult a doctor before taking this medication, and women of childbearing age should avoid pregnancy while taking it. Overdosage may further increase the risk of bleeding, and there is currently no antidote for this medication, so patients should visit a medical facility immediately. The safety and efficacy of this medication have not been established in children, so it is recommended not to use it in those under 18 years of age. If symptoms such as dizziness or confusion occur while taking this medication, it is better to avoid driving or operating machinery. This medication may interact with various medicines, so if taking other medications, patients must inform their healthcare provider.

Hemorrhage, intracranial hemorrhage, ocular hemorrhage, ear hemorrhage, hypotension, dyspnea, respiratory tract hemorrhage, gastrointestinal hemorrhage, diarrhea, nausea, dyspepsia, constipation, retroperitoneal hemorrhage, skin hemorrhage, rash, pruritus, muscle hemorrhage, urinary tract hemorrhage, genital hemorrhage, post-procedural hemorrhage, thrombotic thrombocytopenic purpura, bradyarrhythmia, atrioventricular block, angioedema, Cheyne-Stokes respiration including central sleep apnea, confusion, dizziness, fainting, headache, vertigo, ear hemorrhage, chest pain, pulmonary hemorrhage, pharyngitis, upper respiratory infection, asthma, pleural effusion, bronchitis, pneumothorax, pneumonia, pulmonary edema, weakness, anaphylactic shock, nasal hemorrhage, hemoptysis, hematoma, cerebral hemorrhage, spinal stenosis, dementia, migraine, paralysis, gait abnormalities, rectal hemorrhage, anal hemorrhage, appendicitis, tendinopathy, bursitis, rhabdomyolysis, diabetes, hyperkalemia, hyperglycemia, thirst, hepatitis, snoring, aneurysm, heart failure, cardiac rhythm disorders, palpitations, ventricular tachycardia, arrhythmia, ventricular fibrillation, cardiac arrest, ventricular fibrillation, urinary tract infection, kidney stones, cerebral ischemia, venous stenosis, cerebral infarction, arterial stenosis, angina, coronary thrombosis, myocardial ischemia, anemia, vestibular disorders, malignant neoplasm of the male reproductive system, chemical poisoning, post-procedural hematoma, laceration, road traffic accidents, trauma, nausea, vomiting, acute renal failure, worsening hypertension, orthostatic hypotension, insomnia, anxiety, memory disturbances, erectile dysfunction, agitation, palpitations, bradycardia, atrial fibrillation, conjunctival injection, eye pain, visual disturbances, frequent urination, urinary difficulties, urinary incontinence, urinary retention, azotemia, abscess, oral candidiasis, shingles, bacterial infection, esophageal candidiasis, decreased blood iron, tinnitus, ear pain, lymphadenopathy, eosinophilia, sexual dysfunction, benign prostatic hyperplasia, ovarian cyst, amenorrhea, vaginitis, injection site reactions, injection site pain, increased sweating, urticaria, hypokalemia, hypocalcemia, hypercholesterolemia, lipodystrophy, dehydration, increased AST, increased ALT, drowsiness, neurosis, hallucinations, atrial fibrillation, asystole, ventricular tachycardia, ventricular fibrillation, complete heart block, reaction at the procedural site

This medication must be stored in a tightly sealed container to protect it from exposure to air or moisture. Also, it is important to keep the medicine at room temperature, ideally between 1 and 30 degrees Celsius, avoiding extremes of heat or cold.

Appearance

Pink, round, biconvex film-coated tablet

Package unit

60 tablets - 10 tablets/PTP [60 tablets (10 tablets/PTPX6)]